FDA relaxes cardiovascular trial requirements for diabetes drugs

被引：0
作者：
Asher Mullard [ ]
机构：
来源：
Nature Reviews Drug Discovery | 2020年 / 19卷 / 5期
关键词：
D O I：
10.1038/d41573-020-00071-7
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：298 / 298
相关论文
共 50 条
  • [41] TRENDS IN FDA APPROVALS OF CARDIOVASCULAR DRUGS AND MEDICAL DEVICES (1980-2021)
    Kamerikar, V
    Dheer, P.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2023, 26 (06) : S228 - S229
  • [42] Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies
    Mooghali, Maryam
    Wallach, Joshua D.
    Ross, Joseph S.
    Ramachandran, Reshma
    JAMA NETWORK OPEN, 2024, 7 (08) : e2430486
  • [43] A META-ANALYSIS OF CARDIOVASCULAR SAFETY OF FDA APPROVED ANTI OBESITY DRUGS
    Rehman, Karim Abdur
    Khan, Muhammad
    Rehmani, Arsalan
    Taufeeq, Maryam
    Sheikh, Muhammad Adil
    Fatima, Kaneez
    Gul, Sajjad
    Riaz, Haris
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1668 - 1668
  • [44] New drugs for type 2 diabetes: beyond diabetes, cardiovascular prevention?
    Mannucci, Edoardo
    GIORNALE ITALIANO DI CARDIOLOGIA, 2012, 13 (12) : 3S - 3S
  • [45] Type 2 diabetes : hypoglycaemic drugs and their cardiovascular risks
    Bauduceau, Bernard
    Bordier, Lyse
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2017, 201 (7-9): : 1209 - 1225
  • [46] Cardiovascular outcome trials of diabetes drugs: lessons learned
    Taylor, Simeon I.
    Leslie, Bruce R.
    JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (03) : 893 - 896
  • [47] US relaxes sugar ban for people with diabetes
    Josefson, D
    BRITISH MEDICAL JOURNAL, 2002, 324 (7329): : 70 - 70
  • [48] Divergent Effects of Various Diabetes Drugs on Cardiovascular Prognosis
    Bell, David S. H.
    Patil, Harshal R.
    O'Keefe, James H.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2013, 14 (2-4) : E107 - E122
  • [49] Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes
    Ganda, Om P.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2016, 83 : S11 - S17
  • [50] Metabolic testing after the FDA warning on atypical antipsychotic drugs and diabetes risk
    Morrato, Elaine H.
    Newcomer, John W.
    Kamat, Siddhesh
    Baser, Onur
    Harnett, James
    Cuffel, Brian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S204 - S204
12345